- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE completes deal for IGS firm
Visualization Technology is now part of GE Medical Systems. The deal to acquire the developer of image-guided surgery (IGS) products, announced earlier this year (SCAN 2/20/02), is the second such acquisition by GE. The first, involving Surgical Insights
Visualization Technology is now part of GE Medical Systems. The deal to acquire the developer of image-guided surgery (IGS) products, announced earlier this year (SCAN 2/20/02), is the second such acquisition by GE. The first, involving Surgical Insights of Evanston, IL, closed in February. Visualization Technology is a pioneer in electromagnetic-based IGS. Its innovative technology allows continuous navigation during surgical procedures regardless of the patient's position or the location of surgical instruments.
The new business, called GE Medical Systems Navigation and Visualization, will develop and market IGS products incorporating an open platform that works in conjunction with all manufacturers' intraoperative tools, instruments, devices, and implants. This new business combines the VTI and Surgical Insights product offerings, along with future IGS offerings as they are added to the GE Medical Systems product line. The first product offering from this new business will be the OEC FluoroTrak 9800 Plus, an integrated surgery imaging solution, which will be available this summer.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
